Document is current
Any future updates will be listed below
-
Authors
Hansen, A. L.
Rahbek, L. S. J.
Sørensen, A. S.
Hundahl, M. P.
Lomholt, S.
Holm, C. K.
Kragstrup, Tue W.
-
Funding
Funding for this research was provided by:
Independent Research Fund Denmark (9039-00015B)
- License Information
-
More Information
Article History
Received: 22 March 2021
Accepted: 2 December 2021
First Online: 17 December 2021
Declarations
:
: All samples were obtained after informed written consent according to the Declaration of Helsinki and approved by the Local Ethics Committee (The Central Denmark Region committee on health research ethics, Project Number 20121329) and the Danish Data Protection Agency.
: Not applicable.
: TWK has engaged in educational activities receiving speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, and UCB and has been consultant and advisor for Bristol-Myers Squibb and Gilead. TWK is co-owner and clinical developer in iBiotech ApS developing diagnostic and therapeutic solutions for people with autoimmune diseases and cancer. The other authors have no competing interests.
